Author

Fengtao Zhou

Jinan UniversityORCID 0000-0003-2518-7855Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Ke DingiD· 2 shared Abhijit ParoliaiD· 1 shared Akshara Narayanan· 1 shared Angela Zhang· 1 shared Arul M. ChinnaiyaniD· 1 shared Binghua Zhang· 1 shared Elżbieta KaniaiD· 1 shared Evie RigbyiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ke DingORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Medicinal ChemistryPeer-reviewedOct 4, 2026

Single-Atom Modification Enables Reversal of Degradation Selectivity between NSD2 and GSPT1

Weizhong Shen, Yihan Liu, Lianchao Liu…·Ke Ding

This study modifies a molecule to create two variants with different target selectivity, showing how small structural changes can control degradation activity.

DOI 10.1021/acs.jmedchem.6c01678

experimental assaydrug response / drug discovery

𝕏 PostBluesky

Cancer BiologyBiochemical JournalPeer-reviewedMar 13, 2026

Inducing TRIB2 Targeted Protein Degradation to Reverse Chemoresistance in Acute Myeloid Leukemia

Evie Rigby, Francesca Fasanella Masci, Akshara Narayanan…·Karen Keeshan

This study identifies TRIB2 as a therapeutic target in AML by demonstrating that its degradation via PROTACs and small molecules can reverse chemoresistance and enhance chemotherapy efficacy.

2 citations

humanproteomics

𝕏 PostBluesky